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Summary. Transforming growth factor-betas (TGF-Bs) 
are multifunctional cytokines that exist in 3 isoforms in 
mammals. The TGF-Bs are ubiquitously expressed and 
al1 isoforms are secreted as biologically inactive 
precursors called latent TGF-B (L-TGF- B). LTGF-Bs 
are generally not effective molecules because they are 
unable to interact with their receptors. However, the 
removal of or conformational change of the precursor 
protein called the latency associated peptide (LAP) 
results in the generation of biologically active TGF- B. Zn 
vitro active TGF-B has many biological effects but from 
a clinical point of view one of the most recognized 
associations of aberrant TGF-B production is with 
diseases characterized by enhanced connective tissue 
synthesis. Recently a number of observations in the 
context of fibrotic disorders suggest mechanisms of 
activation of L-TGF-61 in vivo. The recognition of 
mechanisms that activate L-TGF-81 in vivo offers the 
possibiiity of interfering with the activation of L-TGF- 
B 1  for therapeutic purposes. 
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lntroduction 
Transforming growth factor-betas (TGF-Bs) are 
members of a supergene family of proteins that regulate 
numerous biological functions such as embryogenesis, 
growth and differentiation, connective tissue synthesis, 
and immune function (Grande, 1997; Letterio and 
Roberts, 1998; Roberts, 1998; Bonewald, 1999). Three 
of the 5 isoforms of TGF-B are expressed in mammals 
and are called TGF- 1, TGF-B2, and TGF-B3 (Grande, 
1997; Letterio and Roberts, 1998; Roberts, 1998; 
Bonewald, 1999). TGF-B4 is expressed in the chicken 
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(Jakowlew et al., 1988) while TGF-B5 is found in the 
Xenopus (Kondaiah et al., 1990). Since most cells and 
cell lines express TGF-B and its receptors (Grande, 
1997; Letterio and Roberts, 1998; Roberts, 1998; 
Bonewald, 1999) to be biologically effective it is likely 
that there must be a variety of mechanisrns to regulate 
the biological activity of TGF-B. In some instances the 
regulation of TGF-B could occur by the quantity of TGF- 
B produced by changes at the transcriptional (Kelly et 
al., 1995; Roberts, 1998) or post-transcriptional leve1 
(Roberts, 1992, 1998). The production of TGF-B could 
be balanced by the expression of proteins that can bind 
and inactivate or remove TGF-O from the site of 
production. Examples of such proteins are decorin, 
betaglycan, alpha2-macroglobulin, and the latency 
associated peptide (LAP) (Segarini, 1993). It is also 
possible that differential expression of TGF-B signaling 
receptors could also control TGF-B activity (Khalil et al., 
1997). Despite al1 of these possibilities, the most 
important mechanism controlling the effects of TGF-B is 
the post-translational activation of a biologically inactive 
form of TGF-B called latent TGF-B (L-TGF-B) to a 
biologically active form of TGF-B called active or 
mature TGF-B (Khalil, 1999). It is irnportant to realize 
that most mechanisms of activation of L-TGF-B have 
been described using in vitro systems. For this reason it 
remains largely unknown how L-TGF-B is activated in 
vivo. However, there is now growing evidence for in 
vivo mechanisms of activation of LTGF-B especially in 
diseases characterized by increased connective tissue 
synthesis. 
Latent forms of transforming growth factor-beta 
Al1 the TGF-Bs are secreted in a biologically latent 
form called either smail latent TGF-B (L-TGF-B) or large 
L-TGF-B (LL-TGF-0) (Miyazano et al., 1991; 
Bonewald, 1999). Neither of the latent forms of TGF-B 
can interact with the TGF-B signaling receptors and thus 
in most instances are biologically inactive (Miyazano et 
al., 1991; Grande, 1997; Letterio and Roberts, 1998; 
Roberts, 1998; Bonewald, 1999). Each isoform of TGF- 
B is the product of a separate gene and al1 isoforms of 
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TGF-B are initially synthesized as precursor proteins that 
are 390-412 amino acids (Grande, 1997; Roberts, 1998). 
Prior to the secretion of TGF-B by a cell there are a 
number of intracellular processing steps (Miyazano et 
al., 1991; Dubois et al., 1995; McMahon et al., 1996; 
Roberts, 1998). One of these steps is the proteolytic 
cleavage of the TGF-B precursor between amino acids 
278 and 279 by furin, an endopeptidase (Dubois et al., 
1995). The proteolysis results in a 65-75 kDa dimer of 
the N-terminal portion of the TGF-B protein called the 
latency associated peptide (LAP) and a 25 kDa dimer of 
the C-terminal portion of the precursor called the mature 
TGF-B (Dubois et al., 1995; Wakefield et al., 1988). 
Although the precursor is initiaily separated into 2 parts 
the N-terminal portion becomes non-covalently 
associated with the rest of the protein (Dubois et al., 
1995). The association of the LAP with mature TGF-B 
facilitates the transit of the entire TGF-B protein from 
the cell (Miyazano et al., 1991). However, the 
association of LAP with mature TGF-B covers the site 
on TGF-B that interacts with its receptors (Miyazano et 
al., 1991; Dubois et al., 1995). For this reason the 
secreted complex of TGF-B with its LAP is biologically 
inactive and is called latent-TGF-B (L-TGF-B). Once the 
LAP is removed from the mature TGF-B the remaining 
protein is called active or mature TGF-B. 
The structure and function of L-TGF-B1 is described 
most extensively. Each LAP-1 contains a number of 
carbohydrate residues and 2 of the residues have 
mannose-6-phosphate groups (Purchio et al., 1988) 
which can bind to mannose-6-phosphate/insulin like 
growth factor-11 receptor (M-6-P/IGF-11 R) (Kovacina et 
al., 1988). The cysteines in position 223 and 225 in the 
LAP-1 are important for the association of LAP-1 with 
TGF-B1 as well as for dimerization of the LAP-1 
monomers by disulfide binding (Brunner et al., 1989). In 
some instances a cysteine in position 33 of the LAP-1 
binds to another protein called the latent TGF-B binding 
protein-l(LTBP-1) (Saharinen et al., 1996). When L 
TGF-B1 binds to LTBP-1 it is often called large latent 
TGF-B1 (LL-TGF-B1) (Saharinen et al., 1996). There are 
severa1 isoforms of LTBP and each isoform probably 
associates with a specific isoform of GTGF-B. Since the 
LTBPs are coded by genes different from those of L 
TGF-B, LTBP is not an obligatory protein of TGF-B 
(Saharinen et al., 1996). The LTBPs share some common 
characteristics such as 15-19 EGF like repeats, severa1 
cysteines and homology with fibrillins 1 and 2 @allas et 
al., 1995; Taipale et al., 1996). When LTBP-1 is 
associated with the LTGF-8-1 it may cover the M-6-P 
residues on the L-TGF-B1 and thus preventing 
intracellular interaction with the Golgi apparatus 
resulting in facilitation of the exit of L-TGF-B (Purchio 
et al., 1988; Rifkin et al., 1999). LTBP-1 can associate 
with the extracellular matrix (ECM) (Taipale et al., 
1994) and when L-TGF-B1 is complexed with LTBP-1 
the association of LL-TGF-B with the ECM may create a 
reservoir of TGF-61 at an extracellular site (Taipale et 
al., 1994). LTGF-01 in association with LTBP-1 and the 
ECM can be released by proteases to generate active 
TGF-O1 (Dallas et al., 1995; Taipale et al., 1996; Rifkin 
et al., 1999). The release of TGF-B1 from its association 
with the LTBP-1ECM can be remote from the time that 
the TGF-B1 was synthesized and released. This 
possibility suggests that TGF-B1 could be available as a 
biologically effective protein on a chronic basis without 
de novo synthesis. 
Post translational activation of latent TGF-B: plasmin 
dependent mechanisms 
Plasminogen/plasmin proteolytic system 
Zn vitro the LAP from al1 isoforms of L-TGF-B can 
be removed by physiochemical means such as pH of 2 or 
8, 100 "C, chaotropic agents, SDS and urea (Brown et 
al., 1990). More physiological substances described to 
activate L-TGF-B are proteases such as plasmin, calpain 
or endoglycosidase F, sialidase, neuraminidase, 
cathepsins B and D, and the glycoprotein, thrombo- 
spondin-1 (TSP-1) (Miyazano et al., 1991; Schultz- 
Cherry et al., 1995; Khalil, 1999). Although, it is not 
always clear which isoform of TGF-B is susceptible to 
the above mentioned substances, in those studies where 
the isoform is identified it is usually TGF- 81. The 
activation of L-TGF-132 and TGF-B3 is very poorly 
understood. 
Of al1 the substances that activate L-TGF-B1 the 
most common mediator described in the activation of G 
TGF-B1 is the serine protease, plasmin which removes 
the LAP from the latent complex, LAP-TGF-B1 (LTGF- 
B1) (Lyons et al., 1988). Plasmin is derived from 
plasminogen by the proteolytic actions of urokinase 
plasminogen activator (uPA) or tissue type plasminogen 
activator (tPA) (Lijnen, 1996; Reuning et al., 1998). uPA 
activation of plasminogen to plasmin occurs while uPA 
is bound to a specific cell surface receptor, urokinase 
plasminogen activator receptor (UPAR) (Lijnen, 1996; 
Reuning et al., 1998) (Fig. 1). The formation of plasmin 
provides an important source of proteolytic activation of 
L-TGF-B1. tPA has not been clearly identified as binding 
to a cell membrane receptor (Ailan and Martin, 1995; 
Lijnen, 1996; Reuning et al., 1998) and the role of t-PA 
in activation of L-TGF-B is not defined. tPA and uPA 
can be inhibited by the actions of plasminogen activator 
inhibitors (PAI) which exist in at least 4 isoforms (Allan 
and Martin, 1995; Lijnen, 1996; Reuning et al., 1998). 
Receptor bound uPA can be inactivated by PAI-1 when 
the PAI-l/uPAR/uPA complex is intemalized (Ailan and 
Martin, 1995). Once cell surface expression of uPA is 
diminished the generation of plasmin is also reduced 
(Ailan and Martin, 1995). 
Plasmin regulates activation of L-TGF-B in vitro and in 
vivo 
The first reports to describe the activation of cell 
derived L-TGF-B by plasmin was in co-cultures of 
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closely associated could be considered to emulate the in 
vitro co-culture system described above (Antonelli- 
Orlidge et al., 1989; Sato et al., 1990). The presence of 
plasmin in regions of interdigitation could lead to the 
activation of L-TGF-B1 by plasmin. Once activated, the 
TGF-B1 would then inhibit endothelial ceil proliferation 
and terminate further neovascularization (Wakui et al., 
1997). In addition, Herbert and Carmeliet demonstrated 
that when L-TGF-81 was added to serum starved 
vascular SMC it prevented their apoptosis (Herbert and 
Carrneliet, 1997). However, GTGF-B1 added to vascular 
SMC from mice that were obtained with the phenotypes 
uPA-1-, tPA-/-, UPAR-/-, and plasminogen-/- there was no 
effect of LTGF-B1 on vascular SMC apoptosis (Herbert 
and Carmeliet, 1997). These findings suggest that when 
vascular SMC express uPA, UPAR and plasminogen their 
presence activates L-TGF-B leading to vascular SMC 
apoptosis and thus regulation of the bioavailable 
vascular SMC mass. Equaily important are observations 
made by Grainger et al. using transgenic mice that over 
express lipoprotein (a) (Grainger et al., 1994). 
Lipoprotein (Lp(a)) has 2 components, low density 
lipoprotein and apoprotein (a). Lp(a) is approximately 
80% homologous with plasminogen (Grainger et al., 
1994; Grainger and Metcalfe, 1995). When Lp(a) binds 
to endothelial cells and smooth muscle cells it 
competitively inhibits cell associated plasminogen 
activation and therefore there is a decrease in plasmin 
generation (Grainger et al., 1994). The loss of 
plasminogen activation in Lp(a) transgenic mice resulted 
in decrease in active TGF-B in serum and the aortic walls 
(Grainger et al., 1994). The loss of active TGF-B in 
vascular walls was associated with SMC proliferation 
characteristic of atherosclerotic lesions that are seen in 
humans (Grainger et al., 1994; Grainger and Metcalfe, 
1995; Harpel et al., 1995). Collectively these 
observations suggest that plasmin mediated activation of 
L-TGF-B1 is critical in regulating vascular SMC mass. 
The loss of TGF-81 activity as a consequence of plasmin 
deficiency rnay be important in vascular disorders such 
as atherosclerosis and restenosis after angioplasty where 
there is an increase in vascular SMC mass (Harpel et al., 
1995). 
In another example of a clinical disorder that rnay be 
mediated by plasmin activated TGF-B is rheumatoid 
arthritis (Fava et al., 1989; Hamilton et al., 1991). 
Rheumatoid arthritis is a progressive disease of the 
joints. An important feature of rheumatoid arthritis is 
granulation tissue formation in the synovium, which is 
the lining found in joints (Breedveld, 1999). Synovial 
fluid contains increased quantities of uPA and active 
TGF-B1 (Fava et al., 1989; Hamilton et al., 1991). The 
findings suggest that the presence of uPA rnay generate 
plasmin which in tum would lead to an increase in the 
active form of TGF-B1 that could then regulate the 
granulation tissue in the synovium. In yet another 
example, using tissues from patients with chronic 
pancreatitis which is characterized by idiammation and 
fibrosis, immunohistochemical distribution of uPA, 
uPAR and TGF-01 were al1 increased (Freiss et al., 
1997). There was co-localization of uPA, UPAR and 
TGF-61 leading one to speculate that uPA/plasminogen 
interaction could generate plasmin and thus activation of 
L-TGF-B1 and subsequent increase in inflammation and 
extracellular matrix synthesis that is obsewed in chronic 
pancreatitis (Freiss et al., 1997). 
The effect on activation of L-TGF-B by alterations of the 
plaminogen/plasmin system 
Retinoic acid (RA) is a metabolite of vitamin A and 
has been demonstrated to induce the expression of uPA 
and plasmin on the cell membrane of bovine endothelial 
cells (BEC) in vitro (Roberts and Sporn, 1992; Kojima 
and Rifkin, 1993). The induction of uPA and plasmin 
was demonstrated to release active TGF-B by BECs 
(Kojima and Rifkin, 1993). The importance of retinoic 
acid in TGF-B mediated pathogenesis of hepatic fibrosis 
has been described (Knook et al., 1995; Okuro et al., 
1997). Hepatic stellate cells are the major source of 
connective tissue proteins and nodule formation in 
cirrhosis or fibrosis of the liver (Knook et al., 1995; 
Okuro et al., 1997). In vitro TGF-B induces hepatic 
stellate cells to differentiate into myofibroblasts, increase 
extracellular matrix proteins (ECM) and diminish 
degradation of ECM (Knook et al., 1995; Okuro et al., 
1997). In a dose dependent fashion the presence of RA 
induced hepatic stellate cells to increase cell surface 
expression of plasmin and release plasmin as well as 
active TGF-01 (Knook et al., 1995; Okuro et al., 1997). 
In a rat model of hepatic fibrosis induced by porcine 
serum, the administration of RA concomitantly with 
porcine serum compared to porcine serum administration 
alone resulted in a marked increase in total liver TGF-B 
content and hepatic fibrosis (Knook et al., 1995; Okuro 
et al., 1997). These findings would suggest that in vivo 
excessive RA rnay increase the generation of plasmin, 
conversion of LTGF-B to active TGF-B which would in 
turn lead to enhanced hepatic fibrosis (Knook et al., 
1995; Okuro et al., 1997). Recently another interesting 
clinical observation has been made that supports the 
importance of plasmin mediated activation of GTGF-B1 
in vivo (Cai et al., 1997). The use of corticosteroids in 
renal transplant patients is associated with an increased 
incidence of Kaposi's sarcoma while the withdrawal of 
corticosteroids can result in spontaneous regression of 
Kaposi's sarcoma (Cai et al., 1997). Using AID-KS cell 
line it was demonstrated that the generation of TGF-B by 
AIDS-KS ceiis inhibits proliferation of these cells in an 
autocrine manner (Cai et al., 1997). However, in AID-KS 
cells cultured with corticosteroids PAI-1 is increased 
while uPAR is decreased, both events that would 
diminish plasmin generation. The loss of plasmin rnay be 
important in abrogating the generation of active TGF-B 
thus preventing the proliferation of AIDS-KS cells. These 
findings would suggest that the lack of active TGF-B in 
the presence of corticosteroids rnay be pathogenically 
associated with manifestation of Kaposi7s sarcoma. 
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The importance of L-TGF-O association to the cell 
membrane for activation 
In severa1 instances it has been demonstrated that 
although plasmin may be critica1 in releasing TGF-B 
from its association with LAP, that this effect of plasmin 
occurs when L-TGF-B is localized to the cell surface 
(Sato et al., 1990, 1993; Dennis and Rifkin, 1991; 
Miyazano et al., 1991; Kojima and Rifkin, 1993; Khalil 
et al., 1996: Nunes et al., 1997; Wakui et al., 1997). In 
the co-culture model of endothelial cells and pericytes 
the interaction of the mannose-6-phosphate (M-6-P) 
moieties on the LAP with the M-6-P/IGF-11 Rs present 
on the cells in the co-culture is necessary for the 
activation of L-TGF-B (Dennis and Rifkin, 1991; 
Bonewald, 1999). In monocytes M-6-PJIGF-11 acts 
directly with the lysine residues of UPAR (Godar et al., 
1999). The M-6-P/IGF-11 R/uPAR complex then recruits 
severa1 ligands such as uPA, plasminogen and L-TGF-B1 
(Godar et al., 1999). In this manner M-6-PJIGF-11 R 
regulates uPA mediated conversion of plasminogen to 
plasmin (Fig. 1). The plasmin generated remains 
associated with M-6-P/IGF-11 R and is protected from 
inactivation by alpha2-antiplasmin. The cell surface 
association of L-TGF-B1 via the M-6-P/IGF-11 R would 
bring the L-TGF-B spatially closer to the plasminogenl 
plasmin system and to a limited surface area on the cell 
where plasmin is also present (Rifkin Det al., 1999) (Fig. 
1). The plasmin bound to M-6-P/IGF-11 R is then likely 
to be more efficient in the release of active TGF-B1 from 
L-TGF-B which is complexed with M-6-P/IGF-11 R. It is 
unknown if cells other than monocytes that express M-6- 
PIIGF-11 R also form complexes with UPAR, uPA, 
plasminogen and L-TGF-B1. 
The irnportance of the in vivo relevance of activation 
of L-TGF-B1 by M-6-P/IGF-11 R can be speculated by a 
number of reported observations. In a rat model of 
common hile duct ligation there is biliary fibrosis and an 
increase in expression of M-6-P/IGF-11 R and L-TGF-B1 
(Saperstein et al., 1993). These findings suggest that if 
plasmin were present in the periductal space the L-TGF- 
B 1  associated with the M-6-PJIGF-11 R could be 
activated and regulate the increase in connective tissue 
synthesis that was obsewed in this model. Radiotherapy 
to the intestine results in mucosa1 ulceration, 
inflammation, and intestinal wall fibrosis (Wang et al., 
1999). Wang et al. demonstrated that normal intestinal 
epithelial cells express M-6-PIIGF-11 R but after 
irradiation there is shift of M-6-P/IGF-11 R expression to 
intestinal fibroblasts. The expression of M-6-P/IGF-11 R 
on intestinal fibroblasts corresponds to a time of 
maximal connective tissue synthesis (Wang et al., 1999). 
These observations suggest that L-TGF-B1 that is 
released by cells in the vicinity of fibroblasts may 
associate with the M-6-PIIGF-11 R on intestinal 
fibroblasts. In this manner the induction of M-6-P/IGF-11 
R on the fibroblasts may be involved in the activation of 
L-TGF-B1 in vivo and the pathogenesis of radiation 
induced intestinal fibrosis (Wang et al., 1999). Another 
example for the role of M-6-P/IGF-11 R in the activation 
of L-TGF-B1 in vivo are the findings of Sue et al. (1995). 
They demonstrated that there was a 58% decrease in 
expression of M-6-P/IGF-11 R mRNA in hepatocellular 
tumor cells compared to the normal liver surrounding the 
tumor. Using immunohistochemistry normal liver had 
homogeneous co-localized staining with M-6-P/IGF-11 R 
and TGF-B1 (Sue et al., 1995). However, the 
hepatocellular carcinoma had significantly lower levels 
of both M-6-PIIGF-11 R than the normal surrounding 
tissue (Sue et al., 1995). Similar findings were observed 
in phenobarbitol induced hepatic carcinoma (Jirtle et al., 
1994). Liver carcinomas induced by phenobarbitol were 
partially or completely negative for M-6-P/IGF-11 R and 
TGF-B1 compared to the surrounding normal liver tissue 
(Jirtle et al., 1994). Since TGF-B1 is a potent inhibitor of 
epithelial ceil proliferation it is speculated that one of the 
steps in carcinogenesis may be the loss of the ability of 
the epithelial cells to release and respond to the 
antiproliferative effects of TGF-B1 leading to 
autonomous proliferation. The findings from these 
studies suggest that cells unable to activate L-TGF-B 
lose the endogenous antiproliferative effect of TGF-B1 
resulting in uncontrolled proliferation. 
The necessity for L-TGF-81 to associate with the 
cell membrane has been described in another fibrotic 
disorder (Yehaulaeshet et al., 1999). Using a rat model of 
pulmonary fibrosis induced by the antineoplastic 
antibiotic, bleomycin (Yehaulaeshet et al., 1999), 
alveolar macrophages obtained 7 days after bleomycin 
administration released maximal quantities of LTGF-B1 
associated with TSP-1 (Yehaulaeshet et al., 1999). The 
TSP-1LTGF-B1 complex was demonstrated to interact 
with the alveolar macrophage cell membrane by the 
TSP-1 receptor, CD36 prior to the proteolytic effects of 
plasmin (Fig. 1). TSP-1 interacts with CD36 between 
amino acids 93-110 on the ectodomain of CD36 (Lueng 
et al., 1993). A synthetic peptide mimicking this region 
of CD36 prevented the activation of L-TGF-B1 in vitro 
(Yehaulaeshet et al., 1999) and further confirmed that 
localizing L-TGF-B to the cell surface is necessary for 
activation of LTGF-B1. It is of interest that in the rat the 
administration of the CD36 synthetic peptide 93-110 
concomitantly with bleomycin compared to bleomycin 
administration alone resulted in reducing the quantity of 
active TGF-B1 released by alveolar macrophages and 
decreased inflammation and connective tissue synthesis 
(Yehaulaeshet et al., 2000). These findings suggest that 
the association of LTGF-B to alveolar macrophages in 
vivo may be necessary in generating active TGF-81 
(Yehaulaeshet et al., 1999, 2000). Lastly Using co- 
cultures of endothelial cells and pericytes Nunes et al. 
described that LTBP-1/L-TGF-B1 association with the 
cell was also important in activation of L-TGF-B by 
plasmin (Nunes et al., 1997). In addition it was also 
observed that the interaction of LTBP-11 L-TGF-B 1 with 
the ECM required stabilization of cross linking by 
transglutaminases prior to plasmin mediated release of 
the L-TGF-B that was associated with LTBP-1 
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(Flaumenhaft et al., 1993). 
Null mutations of the plasminogen/plasmin system and 
L-TGF-B 1 
The plasminogen/plasmin system has been either 
demonstrated to directly activate L-TGF-B in severa1 
models or is implied to be important in activating L- 
TGF-O1 in an indirect manner. This leads to the puzzling 
observation that mice that have null mutations for 
plasminogen, uPA, UPAR, or PAI-1 do not have lesions 
characteristic of TGF-B1 null mice (Kulkarni et al., 
1993). One could speculate that for physiological 
functions of TGF-B adequate quantities of L-TGF-B are 
converted to active TGF-B by another protease or a 
mechanism independent of proteases. However, it is 
possible that in the event of an injury these mice may 
demonstrate an impaired response to repair due to lack 
of active TGF-B1. For example, mice deficient in both 
uPA and tPA developed cutaneous wounds that healed 
poorly (Herbert and Carmeliet, 1997) and mice deficient 
in plasminogen expression have inadequate repair of 
arteria1 injury (Herbert and Carmeliet, 1997). 
Unfortunately, none of these studies determined if the 
impairment was due to a lack of biologically active 
TGF-B1. It is of interest that in mice that over expressed 
PAI-1 which would be expected to result in diminished 
plasmin production and thus active TGF-B1 had an 
increased quantity of collagen after bleomycin 
administration (Eitzman et al., 1996). Since plasmin 
degrades collagen (Eitzman et al., 1996) it is possible 
that the coliagen synthesis mediated by other cytokines 
albeit less than that observed with TGF-61 would 
accumulate in the absence of plasmin. The increase in 
collagen deposition in these mice could then be 
independent of the leve1 of active TGF-B1. 
Post translational activatlon of latent TGF-O: plasmln 
independent mechanisms 
The activation of L-TGF-B 1 by TSP- 1 
TSP is a trimeric glycoprotein that exists in 5 
isoforms (Lawler et al., 1993). Of these isoforms the 
RFK sequence of TSP-1 has been described by Murphy- 
Ullrich's laboratory to interact with the LAP of GTGF- 
1 derived from bovine aortic endothelial (BAE) cells 
(Schultz-Cherry et al., 1995). This interaction leads to a 
conformational change that exposes the TGF-B receptor 
binding site on the L-TGF-B1 protein resulting in TGF- 
B 1  that can bind to its receptor without releasing the 
LAP (Schultz-Cherry et al., 1995; Ribeiro et al., 1999). 
Unlike the previously discussed mechanisms of 
activation of LTGF-B1, in Murphy-Ullrich's model the 
activation of L-TGF-B1 did not require the presence of 
the plasminogen/plasmin system or cell surface 
localization. More recently an association of TSP-1 with 
TGF-B1 has been described in cells other than bovine 
endothelial cells or alveolar macrophages (Schultz- 
Cherry et al., 1995; Ribeiro et al., 1999; Yehaulaeshet et 
al., 1999). In vitro high concentrations of glucose in 
cultures of renal mesangial cells induces TSP-1 
expression (Tada and Isogai, 1998). The induction of 
TSP-1 by cultures of mesangial cells leads to the release 
of active TGF-B1 which in an autocrine manner 
regulates fibronectin synthesis (Tada and Isogai, 1998). 
In an animal model of glomerulonephritis where there is 
an increase in interstitial fibrosis active TGF-B1 and 
TSP-1 were co-localized, but not TSP-1 and L-TGF-B1 
(Hugo et al., 1998). The in vivo role of TSP-1 in 
activating L-TGF-81 was suggested in congenital 
hepatic fibrosis (El-Youssef et al., 1999). Using 
immunohistochemistry TGF-B1 and TSP-1 were present 
in perisinusoidal regions in the location of hepatic 
stellate cells which are the major source of connective 
tissue proteins in the liver (El-Youssef et al., 1999). One 
could speculate that the presence of both TSP-1 and L- 
TGF-B1 in the hepatic perisinusoidal region or in 
glomerulonephritis could generate active TGF-Bland 
thus regulate increased connective tissue synthesis. The 
activation of L-TGF-B1 by TSP-1 in more physiological 
conditions may also occur. This possibility is supported 
by the observation that TSP-1 null mice (Crawford et al., 
1998) have inflammatory infiltrates in the lungs and 
pancreas similar to those described in TGF-B1 null mice 
(Kulkarni et al., 1993). However, when the TSP-1 null 
mice were treated systemically with injections of KRFK 
peptide, a region of TSP-1 responsible for activating L- 
TGF-81 there was significant abrogation of the 
inflammatory lesions in the lungs and pancreas 
suggesting that critica1 regions of the TSP-1 protein 
activate GTGF-B in vivo (Crawford et al., 1998). 
Angiotensin 11 (Angll) activation of L-TGF-B 1 
Angiotensin 11 is an octapeptide and a major effector 
molecule in the rennin-angiotensin-system (Motojima et 
al., 1999). Originally, AngII was described to regulate 
systemic blood pressure by a direct or indirect 
vasopressive effect (Wolfe and Ziyadeh, 1997). 
However, more recent findings have demonstrated that 
AngII promotes cellular proliferation and ECM 
accumulation in vascular SMC and glomerular 
mesangial cells leading to glomerulosclerosis and 
cardiovascular disease (Wolfe and Ziyadeh, 1997). 
AngII is activated by the actions of angiotensin 
converting enzyme (ACE) which can be inhibited by a 
number of ACE inhibitors (Wolfe and Ziyadeh, 1997). 
AngII is elevated in severa1 models of renal disease 
where there is evidence of hypertrophy of glomerular 
and tubular structures, thickening of glomerular and 
tubular basement membrane that result in obliteration of 
glomerular capillaries, tubulointerstitial fibrosis, renal 
arteriosclerosis, and ultimately renal failure (Border and 
Noble, 1997). AngII induces renal mesangial and renal 
tubular cells to release active TGF-B (Kagami et al., 
1994; Border and Noble, 1997). The release of TGF-81 
results in increased connective tissue synthesis by the 
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mesangial cells in an autocrine fashion (Kagami et al., 
1994). Continuous in vivo administration of AngII to 
normal rats increased glomerular mRNA of TGF-B1 and 
collagen 1 (Kagami et al., 1994). These effects of AngII 
were inactivated by ACE inhibitors, AngII receptor 
antagonists and antibodies to TGF-B1 (Kagami et al., 
1994; Wolfe and Ziyadeh, 1997). Taken together these 
observations suggest that AngII induces the release of 
active TGF-B which in turn results in induction of 
connective tissue proteins in the kidney. The 
mechanisms by which AngII activates L-TGF-61 has not 
been clearly defined. However, since AngII increases 
plasminogen activator and decreases plasminogen 
activator inhibitor-1 it could lead to an induction of 
plasmin and the conversion of L-TGF-B to its active 
form (Fogo, 2000). The induction of uPA and plasmin by 
AngII may occur in the kidney, but this has not yet been 
described. 
Activation of TGF-B by hyperglycemia 
Although AngII has been described to be important 
in renal fibrosis, it has also been demonstrated that 
hyperglycemia leads to similar fibrotic lesions in the 
kidney as described above (Sharma and Ziyadeh, 1995). 
In the presence of high glucose concentrations cultured 
mesangial cells (Hoffman et al., 1998), proximal tubular 
cells (Wolf and Ziyadeh, 1999), and glomerular 
epithelial cells (van Det et al., 1997) lead to induction of 
TGF-B mRNA and the release of biologically active 
TGF-B (van Det et al., 1997; Hoffman et al., 1998; Wolf 
and Ziyadeh, 1999). It is of interest that the renal 
proximal tubular cells from TGF-B WO mice do not 
release TGF-B or synthesize collagen in response to 
hyperglycemia as do their normal counterparts (Wolf and 
Ziyadeh, 1999). Furthermore, in streptozotocin (STZ) 
induced diabetic mice there is increase in renal mRNA 
TGF-B1 and ECM proteins (Sharma and Ziyadeh, 1995). 
Treatment of STZ-diabetic mice with insulin reduced 
renal hypertension, and decreased mRNA expression of 
TGF-B, collagen IV and fibronectin synthesis (Sharma 
and Ziyadeh, 1995). Additionally, in patients with 
established diabetic nephropathy there is increased 
expression of TGF-B protein (Sharma and Ziyadeh, 
1995; vanDet et al., 1997; Hoffman et al., 1998; Wolf 
and Ziyadeh, 1999). Based on the in vitro data and 
animal models of renal fibrosis or glomerulosclerosis 
one can speculate that hyperglycemia induces active 
TGF-B1 release that is then important in the increased 
expression of ECM proteins seen in lesions of 
glomerulosclerosis. The mechanism by which 
hyperglycemia releases active TGF-B is unknown. 
Hyperglycemia induces protein kinase C and oxidative 
metabolites (Struder et al., 1997). In the presence of anti- 
oxidants such as a-tocopherol, taurine, and N- 
acetylcysteine there is inhibition of the release of active 
TGF-B and TGF-B mediated synthesis of the ECM in 
response to hyperglycemia (Struder et al., 1997). These 
observations would suggest that hyperglycemia may 
generate reactive oxygen species (ROS) that lead to 
activation of L-TGF-B1. 
Reactive oxygen species activate L-TGF-B 1 
When recombinant native human L-TGF-B (rL- 
TGF-B1) is irradiated with 50-200 Gy of *Coy in iron 
containing saline there is generation of active TGF-81 
(Barellos-Hoff et al., 1996). To determine if ROS 
released by gamma radiation could activate L-TGF-B, 
ROS were generated by oxidation of ascorbate catalyzed 
by F~+~/EDTA or ~ a + ~  in a solution with rL-TGF-81 
which resulted in activation of the rL-TGF-81 
(Barcellos-Hoff et al., 1996). The mechanism by which 
ROS could activate LTGF-B1 may be due to the effects 
of ROS on the LAP-1. Cysteine and methionine located 
on the LAP are susceptible to oxidation which could 
lead to sufficient changes in the LAP-1 that the 
association of LAP-1 with LTGF-B could become very 
unstable. Such instability could either release TGF-B1 or 
undergo conformational change to expose the TGF-B 
receptor binding site (Barcellos-Hoff et al., 1996). The 
biological significance of these findings were confirmed 
by the same group (Barcellos-Hoff et al., 1994). The 
irnrnunohistochemical distribution of active and GTGF- 
B 1  in mammary gland tissue of mice after irradiation 
were examined and compared to normal mammary gland 
tissue (Barcellos-Hoff et al., 1994). The antibody 
described as anti-LAP-1 detects L-TGF-81 while the 
antibody designated as anti-LC-1-30 recognizes an 
epitope of TGF-81 only when the LAP-1 is not present 
and thus anti-LC-1-30 recognizes biologically active 
TGF-81 (Barcellos-Hoff et al., 1995). Barcellos-Hoff et. 
al. demonstrated in normal epithelium that there was little 
staining with the anti-LC-1-30 antibody yet after 
irradiation there was prominent staining with the anti-LC 
antibody and the staining co-localized with collagen 
(Barcellos-Hoff et al., 1994). These findings are 
clinically significant because TGF-B1 is a potent inducer 
of connective tissue synthesis (Grande, 1997; Letterio 
and Roberts, 1998; Roberts, 1998; Bonewald, 1999) and 
it is well recognized that irradiation of human tissue can 
lead to fibrosis (Barcellos-Hoff et al., 1994). It is then 
possible that GTGF-61 activated by ROS generated fiom 
radiotherapy then induces comective tissue synthesis. 
The integrin avB6 activates L-TGF-B 1 
Munger et al. described that the RGD (arginine- 
glycine-aspartic acid) sequences present in the LAP-1 of 
LTGF-B1 complexes with the integrin avB6 located on 
epithelial cells (Munger et al., 1999). Once LTGF-Bl 
interacts with the avB6 on epithelial cells the 86 
cytoplasmic domain associates with the actin in the 
cytoskeleton of the cell. This interaction of GTGF-61 
with avB6 leads to a conformational change in the L- 
TGF-B1 still anchored to the cell membrane such that the 
mature TGF-B1 interacts with the TGF-B receptor type 11 
located in close vicinity of the LTGF-B1-avB6 complex 
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(Munger et al., 1999) (Fig. 1). These findings suggest 
that the presence of L-TGF-B by epithelial cells that 
express avB6 the GTGF-B1 can have a biological effect 
without being released from its association with LAP or 
requiring a protease (Munger et al., 1999). The 
association of LTGF-B with avB6 located on epithelial 
ceils rnay be important in vivo. For example, when mice 
with an avB6 WO defect are given bleomycin there was 
markedly less pulmonary fibrosis than when compared 
to bleomycin administration to the wild type (Munger et 
al., 1999). Another example of a role for avB6 in 
regulating L-TGF-B is in cutaneous wounding. One of 
the most important events in cutaneous wound closure is 
the formation of an epithelial tongue of migrating 
keratinocytes at the edge of the wound (Zambruno et al., 
1995). The keratinocytes at the wound edge are highly 
migratory, do not proliferate and express avB6 
(Zambruno et al., 1995). TGF-B is present in increased 
quantities in the wounds and induces avB6 expression 
by keratinocytes (Zambruno et al., 1995). TGF-B 
enhances motility of cells and is antiproliferative to 
epithelial cells suggesting that TGF-B which is abundant 
at sites of wounding could associate with avB6 on 
migrating keratinocytes, become activated, and induce 
migration of these cells while maintaining their low 
proliferative index. 
Mechanical stretching activates L-TGF-B 
In normal renal function mesangial cells serve as 
part of a support structure for the glomerular loop 
(Ingram et al., 1999). in vivo mesangial cells are 
consistently exposed to cyclic stretch and relaxation 
(Ingram et al., 1999). The stretching of mesangial cells is 
particularly likely to occur in situations of glomerular 
hypertension which is associated with glomerulo- 
sclerosis. Explanted mesangial cells or those obtained 
from a cell line when exposed to mechanical stretching 
were induced to increase the expression of TGF-B on the 
surface of the mesangial cell (Hirakata et al., 1997) and 
release active TGF-B into the conditional media (Ingram 
et al., 1999). The release of active TGF-B by the 
mesangial cells in an autocrine manner led to connective 
tissue synthesis (Ingram et al., 1999). The mechanism by 
which stretching induces TGF-B is not well understood, 
but stretching induces protein kinase C (PKC) and 
inhibitors of PKC can lead to attenuation of the stretch 
induced mediated induction of TGF-B (Hirakata et al., 
1997). However, it remains unclear how stretching of 
mesangial cells leads to the increased release of active 
TGF-B. One can speculate that since vascular smooth 
muscle injury leads to induction of plasmin generation 
by an undefined mechanism it is conceivable that 
stretching of the mesangial cells rnay be important in the 
generation of plasmin which would lead to the activation 
of L-TGF-B. There is  another suggestion of how 
stretching rnay lead to the release of L-TGF-B. 
Stretching deformity of mesangial cells also induces the 
release of LTBP-1 (Hori et al., 1998) which has been 
reported to localize TGF-B to the cell surface prior to 
plasmin mediated activation of L-TGF-B (Flaumenhaft et 
al., 1993). It is then conceivable that the process of 
stretching rnay mediate the activation of L-TGF-B by 
induction of LTBP-1. 
Summary and concluslon 
Even though many observations support the 
importance of the plasminogen/plasmin system for 
activation of L-TGF-B1 in vitro and in vivo there is 
sufficient evidence to demonstrate that one universal 
mechanism of activation of L-TGF-B is unlikely. Just as 
the biological functions of TGF-B are highly context 
dependent it seems probable that the activation of L- 
TGF-II is also very context dependent. For example in 
the liver activation of GTGF-B1 seems to be supported 
by data suggesting that the expression of M-6-P/IGF-11 
R has a major role in L-TGF-B1 activation (Saperstein et 
al., 1993; Jirtle et al., 1994; Sue et al., 1995; Godar et al., 
1999). In the kidney AngII, mechanical stretching, TSP- 
1 and hyperglycemia appear to activate L-TGF-B1 
(Kagamami et al., 1994; Sharma and Ziyadeh, 1995; 
Border and Noble, 1997; van Det, 1997; Struder et al., 
1997; Wolf and Ziyadeh, 1997, 1999; Hoffman et al., 
1998; Motojima et al., 1999). In the lung the expression 
of cell surface adhesion proteins like avB6 and CD36 
have been demonstrated to be necessary for the 
activation of L-TGF-81 (Munger et al., 1999; 
Yehaulaeshet et al., 1999). Whereas, the activation of L 
TGF-B1 by TSP-1 and ROS rnay not be organ specific. It 
is also possible that during the course of repair by 
fibrosis or in disorders characterized by enhanced 
connective tissue synthesis that more than one 
mechanism of activation of L-TGF-Bl rnay be involved. 
For example early in the course of a fibrotic disorder 
infiltrating macrophages rnay be a prominent source of 
active TGF-61 (Yehaulaeshet et al., 1999). In this early 
stage the activation rnay involve the CD36-TSP-1/L- 
TGF-81 or L-TGF-B1/M-6-P-IGF-11 R complexes and 
plasmin (Godar et al., 1999; Yehaulaeshet et al., 1999). 
However, later in the course of the disease structural 
cells such as epithelial or endothelial cells rnay be 
important in activation of LTGF-B by the interaction of 
L-TGF-B1 with M-6-P/IGF-11 R (Sato et al., 1990) or 
avB6 and be independent of plasmin (Munger et al., 
1999). Currently a number of progressive diseases have 
been associated with the aberrant expression of TGF-B1 
(Border and Noble, 1994). Some examples are idiopathic 
pulmonary fibrosis, scleroderma, cirrhosis of the liver, 
glomerulosclerosis, and post-lung transplant bronchio- 
litis obliterans (Border and Noble, 1994; Bergman et al., 
1998). These diseases rarely if at al1 respond to the 
standard therapy using immuno-suppressive agents. 
Understanding the mechanisms of activation of L-TGF- 
B 1  in these disease processes rnay then direct the 
development of therapeutic agents that could retard or 
prevent further progression of fibrosis resulting in 
reduced morbidity and mortality. 
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